- Trial Phase
- Preclinical / IND-cleared
- Time to Market
- Unknown — BA3361 has not entered clinical trials. Even if partnered/licensed, typical development timelines for an ADC from Phase 1 to approval are 5-8+ years. Given BioAtla's financial situation, the drug is more likely to be sold to a partner who would then bear development costs.
- Why 2/10
- No hard, dated catalyst is scheduled for BA3361 in the next ~12 months. The drug is preclinical/IND-cleared with no clinical trial started. The company is in survival mode (strategic review, delisted, 70% workforce cut). BA3361 is one of several pipeline assets being shopped; any value realization would come via a partnership/sale, not a clinical readout. ImpactScore is 2: a preclinical program at a distressed company with no near-term binary catalyst.
BA3361 is a preclinical pipeline asset at a company fighting for survival. The key catalyst for BCAB is not a BA3361 readout but the strategic alternatives process — watch for asset sales, licensing deals, or a merger. With only ~$1.5M cash and a going concern warning, any positive news on BA3361 would likely come via a partnership or sale, not internal development. The stock is highly speculative and trades on OTC with minimal liquidity.
Price Chart
Executive Summary
BA3361 is a preclinical-stage, IND-cleared NextGen Conditionally Active Biologic (CAB) antibody-drug conjugate (ADC) targeting Nectin-4, developed by BioAtla (BCAB). It has shown promising preclinical activity in PDX models of lung, bladder, breast, and pancreatic cancers, with pH-selective tumor targeting designed to reduce off-tumor toxicity. However, BioAtla is in severe financial distress — only ~$1.5M cash as of mid-2026, delisted from Nasdaq to OTCQB, 70% workforce reduction, and a formal strategic alternatives process underway to sell assets. BA3361 has not yet entered clinical trials, and the company's survival depends on finding a buyer or partner for its pipeline. The drug is unlikely to generate any near-term value for BCAB shareholders.
How It Works
BA3361 is an antibody-drug conjugate (ADC) — a targeted cancer therapy that works like a guided missile. The antibody portion seeks out Nectin-4, a protein found on the surface of many cancer cells (lung, breast, bladder, pancreatic). Once bound, it releases a chemotherapy payload directly inside the cancer cell. BioAtla's 'Conditionally Active Biologic' (CAB) technology makes the antibody only bind strongly in the acidic environment found around tumors, not in healthy tissue, which is designed to reduce side effects compared to standard Nectin-4 ADCs like enfortumab vedotin (Padcev).
Trial Status
BA3361 received FDA clearance of its Investigational New Drug (IND) application, enabling the start of clinical trials. However, no clinical trial has been initiated as of the latest filings. Preclinical data has been presented at AACR 2024 and AACR 2025, showing potent activity in patient-derived xenograft (PDX) models of lung, bladder, breast, and pancreatic cancers. The company's financial distress (only ~$1.5M cash, 70% workforce reduction) has paused or delayed clinical advancement.
The Two-Sided Case
Upcoming Catalysts
- Strategic alternatives outcome (potential sale/license of BA3361 or entire pipeline)
- Partnership or licensing deal for BA3361
- Any clinical trial initiation (unlikely without new funding/partner)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BioAtla, Inc. S-1 BCAB ·Originating report